CDDO-dhTFEA

CDDO-dhTFEA

• CAS Number: 1191265-33-4
• UNSPSC Description: CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB[1]. CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats[2].
• Target Antigen: Keap1-Nrf2; NF-κB
• Type: Reference compound
• Related Pathways: NF-κB
• Applications: Neuroscience-Neuromodulation
• Field of Research: Inflammation/Immunology; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/cddo-dhtfea.html
• Purity: 99.71
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(NCC(F)(F)F)=O)C)4C)5[H])C(C(C#N)=C[C@]5(C)[C@@]4([H])CC3=O)=O
• Molecular Weight: 574.72
• References & Citations: [1]Aminzadeh MA, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease. Redox Biol. 2013 Oct 31;1:527-31.|[2]Aminzadeh MA, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014 Jun;44(6):570-8.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported